» Articles » PMID: 39744100

Development and Assessment of a Novel Magnetic Nanoparticle Antibody-conjugate and Aptamer-based Assay (MNp-Ab-Ap Assay) for the Rapid Diagnosis of Pleural Tuberculosis

Abstract

Pleural tuberculosis (pTB) is a diagnostic challenge because of its non-specific clinical features, lack of accurate diagnostic tools and paucibacillary nature of the disease. We, here describe the development of a novel magnetic nanoparticle antibody-conjugate and aptamer-based assay (MNp-Ab-Ap assay) targeting 4 different (. ) antigens (GlcB, MPT51, MPT64 and CFP-10) for pTB diagnosis. The MNp-Ab-Ap assay was developed by conjugating polyclonal antibodies on the surface of magnetic nanoparticles (MNPs) by using EDC-NHS chemistry. These conjugated MNPs were used to capture antigens present in the pleural fluid samples. The resulting antigen-antibody complex was detected by antigen-specific 5'-biotinylated aptamers. All assays were standardized using samples of the 'Development set' (n=17) and evaluated in the 'Validation set' (n=114) in a blinded manner. Patient categorization was done using a 'Composite Reference Standard'. Assay cut-offs were determined from the 'Development set' (n=17; 'Definite & Probable' pTB; n=9 and 'Non-TB'; n=8) by calculating mean+3SD of OD values of the 'Non-TB' group and applied to 'Validation set' (n=114; 'Definite' pTB; n=8, 'Probable' pTB; n=34, 'Possible' pTB; n=28 and 'Non-TB'; n=44). Out of the 4 assays, MPT51-based MNp-Ab-Ap assay performed the best with 66.6% (95%CI;50.4-80.4) sensitivity and 95.4% (95%CI;85.1-99.4) specificity in the combined 'Definite and Probable' pTB group. Xpert MTB/RIF assay detected only six samples in the 'Validation set'. Binary logistic regression analysis indicated that MPT51-based MNp-Ab-Ap assay provided an incremental advantage over the existing diagnostic algorithm for pTB. We conclude that MPT51-based MNp-Ab-Ap assay is a novel technique that can pave the way towards rapid and accurate diagnosis of pTB.

References
1.
Kaur H, Bruno J, Kumar A, Sharma T . Aptamers in the Therapeutics and Diagnostics Pipelines. Theranostics. 2018; 8(15):4016-4032. PMC: 6096388. DOI: 10.7150/thno.25958. View

2.
Kumar Saini D, Pant N, Das T, Sivaswami Tyagi J . Cloning, overexpression, purification, and matrix-assisted refolding of DevS (Rv 3132c) histidine protein kinase of Mycobacterium tuberculosis. Protein Expr Purif. 2002; 25(1):203-8. DOI: 10.1006/prep.2002.1628. View

3.
Sypabekova M, Bekmurzayeva A, Wang R, Li Y, Nogues C, Kanayeva D . Selection, characterization, and application of DNA aptamers for detection of Mycobacterium tuberculosis secreted protein MPT64. Tuberculosis (Edinb). 2017; 104:70-78. DOI: 10.1016/j.tube.2017.03.004. View

4.
Liang Q, Pang Y, Yang Y, Li H, Guo C, Yang X . An improved algorithm for rapid diagnosis of pleural tuberculosis from pleural effusion by combined testing with GeneXpert MTB/RIF and an anti-LAM antibody-based assay. BMC Infect Dis. 2019; 19(1):548. PMC: 6588860. DOI: 10.1186/s12879-019-4166-1. View

5.
Tang X, Zhou Y, Wu S, Pan Q, Xia B, Zhang X . CFP10 and ESAT6 aptamers as effective Mycobacterial antigen diagnostic reagents. J Infect. 2014; 69(6):569-80. DOI: 10.1016/j.jinf.2014.05.015. View